QUAESTOR BIOTECH: what changed
Two financial years side by side, explained: what moved most in the balance sheet and the result, why the result rose or fell, and where the money went.
QUAESTOR BIOTECH
Largest movements
- Financial fixed assets +€1.7m
up €1.7m (+16.4%), from €10.3m to €11.9m
- Cash -€229,302
down €229,302 (-17.0%), from €1.3m to €1.1m
mainly Investment in fixed assets (net) (-€1.7m) and Net result for the year (-€887,106)
- Contributions +€2.3m
up €2.3m (+18.1%), from €12.9m to €15.2m
- Profit (loss) carried forward -€887,106
down €887,106 (-65.7%), from -€1.3m to -€2.2m
- Financial income -€590,800
down €590,800 (-99.4%), from €594,198 to €3,398
of which Non-recurring financial income: -€577,953
- Financial charges +€378,616
up €378,616 (+105%), from €359,105 to €737,722
of which Non-recurring financial charges: +€378,737
- Gross operating margin -€9,774
down €9,774 (-7.4%), from -€132,175 to -€141,949
From the 2024 result to the 2025 result
Each bar is the change in one income-statement line, as its effect on the result: higher costs pull it down, higher income lifts it.
Derived cash bridge
Derived from the 2024 and 2025 balance sheets and the 2025 result: not a filed cash-flow statement. It shows where the money came from and went.
Every line side by side
| Line | Code | 2024 | 2025 | Change | % |
|---|---|---|---|---|---|
| Total assets | 20/58 | €11,615,164 | €13,058,798 | +€1.4m | +12.4% |
| Formation expenses | 20 | €9,620 | €0 | -€9,620 | -100% |
| Fixed assets | 21/28 | €10,259,932 | €11,942,456 | +€1.7m | +16.4% |
| Financial fixed assets | 28 | €10,259,932 | €11,942,456 | +€1.7m | +16.4% |
| Current assets | 29/58 | €1,345,612 | €1,116,342 | -€229,270 | -17.0% |
| Cash at bank and in hand | 54/58 | €1,345,533 | €1,116,231 | -€229,302 | -17.0% |
| Deferred charges and accrued income | 490/1 | €79 | €111 | +€32 | +40.9% |
| Total equity and liabilities | 10/49 | €11,615,164 | €13,058,798 | +€1.4m | +12.4% |
| Equity | 10/15 | €11,547,438 | €12,990,332 | +€1.4m | +12.5% |
| Contributions | 10/11 | €12,896,750 | €15,226,750 | +€2.3m | +18.1% |
| Profit (loss) carried forward | 14 | -€1,349,312 | -€2,236,418 | -€887,106 | -65.7% |
| Amounts payable | 17/49 | €67,726 | €68,466 | +€740 | +1.1% |
| Amounts payable within one year | 42/48 | €67,726 | €68,466 | +€740 | +1.1% |
| Trade debts | 44 | €67,726 | €68,466 | +€740 | +1.1% |
| Suppliers | 440/4 | €67,726 | €68,466 | +€740 | +1.1% |
| Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets | 630 | €9,820 | €9,620 | -€200 | -2.0% |
| Other operating charges | 640/8 | €1,179 | €1,214 | +€36 | +3.0% |
| Gross operating margin | 9900 | -€132,175 | -€141,949 | -€9,774 | -7.4% |
| Operating profit (loss) | 9901 | -€143,173 | -€152,783 | -€9,610 | -6.7% |
| Financial income | 75/76B | €594,198 | €3,398 | -€590,800 | -99.4% |
| Recurring financial income | 75 | €16,245 | €3,398 | -€12,847 | -79.1% |
| Non-recurring financial income | 76B | €577,953 | €0 | -€577,953 | -100% |
| Financial charges | 65/66B | €359,105 | €737,722 | +€378,616 | +105% |
| Recurring financial charges | 65 | €1,950 | €1,829 | -€121 | -6.2% |
| Non-recurring financial charges | 66B | €357,155 | €735,892 | +€378,737 | +106% |
| Profit (loss) for the period before taxes | 9903 | €91,920 | -€887,106 | -€979,026 | |
| Income taxes | 67/77 | -€190 | €0 | +€190 | |
| Profit (loss) for the period | 9904 | €92,110 | -€887,106 | -€979,216 | |
| Profit (loss) for the period to be appropriated | 9905 | €92,110 | -€887,106 | -€979,216 |
Source: filed annual accounts (NBB), financial years ended 31 December 2024 and 31 December 2025. Colour: green is a favourable move for that line, red an unfavourable one. Prepared on 25 October 2026 via checked.be.